Bimagrumab: an investigational human monoclonal antibody against activin type II receptors for treating obesity.
activin type II receptors (ActRII)
bimagrumab
myostatin
obesity
Journal
Journal of basic and clinical physiology and pharmacology
ISSN: 2191-0286
Titre abrégé: J Basic Clin Physiol Pharmacol
Pays: Germany
ID NLM: 9101750
Informations de publication
Date de publication:
10 Oct 2024
10 Oct 2024
Historique:
received:
27
04
2024
accepted:
19
09
2024
medline:
10
10
2024
pubmed:
10
10
2024
entrez:
10
10
2024
Statut:
aheadofprint
Résumé
Bimagrumab is a human monoclonal antibody that prevents activin type II receptors (ActRII) from functioning. This antibody has a higher affinity for muscle activin-2 receptors than natural ligands such as activin and myostatin, which act as negative muscle growth regulators. Blocking the activin receptor with bimagrumab could be a new pharmaceutical approach for managing patients with obesity and type 2 diabetes mellitus (T2DM). Bimagrumab has anabolic effects on skeletal muscle mass by preventing myostatin binding and other negative muscle growth regulators. Preclinical animal models have also shown that ActRII blockade promotes actions beyond skeletal muscle, including effects on brown adipose tissue (BAT) differentiation and activity. In a phase 2 randomized clinical trial, ActRII blockade with bimagrumab led to significant loss of total body fat mass (FM), lean mass (LM) gain, and metabolic improvements over 48 weeks in overweight or obese patients with type 2 diabetes. The trial involved [number of participants], and the results showed [specific findings]. Currently, Bimagrumab is being evaluated for its potential to treat muscle wasting, functional loss in hip fractures and sarcopenia, as well as obesity. However, it is essential to note that Bimagrumab also blocks the effects of other ActRII ligands, which play a role in the neurohormonal axes, pituitary, gonads, and adrenal glands. These observations suggest that bimagrumab might represent a new approach for treating patients with obesity and related metabolic disturbances.
Identifiants
pubmed: 39385353
pii: jbcpp-2024-0065
doi: 10.1515/jbcpp-2024-0065
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Walter de Gruyter GmbH, Berlin/Boston.
Références
Kaur, M, Misra, S. A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. Eur J Clin Pharmacol 2024. https://doi.org/10.1007/s00228-024-03646-0 .
doi: 10.1007/s00228-024-03646-0
World obesity atlas; 2022. Available from: https://s3-eu-west-1.amazonaws.com/wof-files/World_Obesity_Atlas_2022.pdf [Accessed 7 November 2022].
International Diabetes Federation Diabetes Atlas . IDF_Atlas_10th_Edition_2021.pdf ; 2021. Available from: https://diabetesatlas.org/ [Accessed 7 November 2022].
Iglay, K, Hannachi, H, Howie, PJ, Xu, J, Li, X, Engelet, SS, et al.. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Curr Med Res Opin 2016;32:1243–52. https://doi.org/10.1185/03007995.2016.1168291 .
doi: 10.1185/03007995.2016.1168291
Evert, AB, Franz, MJ. Why weight loss maintenance is difficult. Diabetes Spectr 2017;30:153–6. https://doi.org/10.2337/ds017-0025 .
doi: 10.2337/ds017-0025
Müller, TD, Blüher, M, Tschöp, MH, DiMarchi, RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov 2022;21:201–23. https://doi.org/10.1038/s41573-021-00337-8 .
doi: 10.1038/s41573-021-00337-8
Argiles, JM, Orpi, M, Busquets, S, Lopez-Soriano, FJ. Myostatin: more than just a regulator of muscle mass. Drug Discov Today 2012;17:702–9. https://doi.org/10.1016/j.drudis.2012.02.001 .
doi: 10.1016/j.drudis.2012.02.001
Elkina, Y, von, HS, Anker, SD, Springer, J. The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle 2011;2:143–51. https://doi.org/10.1007/s13539-011-0035-5 .
doi: 10.1007/s13539-011-0035-5
Lach‐Trifilieff, E, Minetti, GC, Sheppard, K, Ibebunjo, C, Feige, JN, Hartmann, S, et al.. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol 2014;34:606–18. https://doi.org/10.1128/mcb.01307-13 .
doi: 10.1128/mcb.01307-13
Lee, SJ. Regulation of muscle mass by myostatin. Ann Rev Cell Dev Biol 2004;20:61–86. https://doi.org/10.1146/annurev.cellbio.20.012103.135836 .
doi: 10.1146/annurev.cellbio.20.012103.135836
Trendelenburg, AU, Meyer, A, Rohner, D, Boyle, J, Hatakeyama, S, Glass, DJ. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am J Physiol Cell Physiol 2009;296:C1258–70. https://doi.org/10.1152/ajpcell.00105.2009 .
doi: 10.1152/ajpcell.00105.2009
Lee, SJ, McPherron, AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA 2001;98:9306–11. https://doi.org/10.1073/pnas.151270098 .
doi: 10.1073/pnas.151270098
Lee, SJ, Reed, LA, Davies, MV, Girgenrath, S, Goad, ME, Tomkinson, KN, et al.. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci USA 2005;102:18117–22. https://doi.org/10.1073/pnas.0505996102 .
doi: 10.1073/pnas.0505996102
Tan, CK, Leuenberger, N, Tan, MJ, Yan, YW, Chen, Y, Kambadur, R, et al.. Smad3 deficiency in mice protects against insulin resistance and obesity induced by a high-fat diet. Diabetes 2011;60:464–76. https://doi.org/10.2337/db10-0801 .
doi: 10.2337/db10-0801
Goncalves, MD, Pistilli, EE, Balduzzi, A, Birnbaum, MJ, Lachey, J, Khurana, TS, et al.. Akt deficiency attenuates muscle size and function but not the response to ActRIIB inhibition. PLoS One 2010;5:e12707. https://doi.org/10.1371/journal.pone.0012707 .
doi: 10.1371/journal.pone.0012707
LeBrasseur, NK, Schelhorn, TM, Bernardo, BL, Cosgrove, PG, Loria, PM, Brown, TA. Myostatin inhibition enhances the effects of exercise on performance and metabolic outcomes in aged mice. J Gerontol A Biol Sci Med Sci 2009;64:940–8. https://doi.org/10.1093/gerona/glp068 .
doi: 10.1093/gerona/glp068
Rebbapragada, A, Benchabane, H, Wrana, JL, Celeste, AJ, Attisano, L. Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol Cell Biol 2003;23:7230–42. https://doi.org/10.1128/mcb.23.20.7230-7242.2003 .
doi: 10.1128/mcb.23.20.7230-7242.2003
McPherron, AC, Lee, SJ. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci U S A 1997;94:12457–61. https://doi.org/10.1073/pnas.94.23.12457 .
doi: 10.1073/pnas.94.23.12457
McPherron, AC, Lawler, AM, Lee, SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997;387:83–90. https://doi.org/10.1038/387083a0 .
doi: 10.1038/387083a0
Mosher, DS, Quignon, P, Bustamante, CD, Sutter, NB, Mellersh, CS, Parker, HG, et al.. A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet 2007;3:e79. https://doi.org/10.1371/journal.pgen.0030079.eor .
doi: 10.1371/journal.pgen.0030079.eor
Schuelke, M, Wagner, KR, Stolz, LE, Hubner, C, Riebel, T, Komen, W, et al.. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 2004;350:2682–8. https://doi.org/10.1056/nejmoa040933 .
doi: 10.1056/nejmoa040933
Allen, DL, Cleary, AS, Speaker, KJ, Lindsay, SF, Uyenishi, J, Reed, JM, et al.. Myostatin, activin receptor IIb, and follistatin-like-3 gene expression are altered in adipose tissue and skeletal muscle of obese mice. Am J Physiol Endocrinol Metab 2008;294:E918–927. https://doi.org/10.1152/ajpendo.00798.2007 .
doi: 10.1152/ajpendo.00798.2007
Hittel, DS, Berggren, JR, Shearer, J, Boyle, K, Houmard, JA. Increased secretion and expression of myostatin in skeletal muscle from extremely obese women. Diabetes 2009;58:30–8. https://doi.org/10.2337/db08-0943 .
doi: 10.2337/db08-0943
Lee, SJ, Reed, LA, Davies, MV, Girgenrath, S, Goad, ME, Tomkinson, KN, et al.. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci USA 2005;102:18117–22. https://doi.org/10.1073/pnas.0505996102 .
doi: 10.1073/pnas.0505996102
Wilkes, JJ, Lloyd, DJ, Gekakis, N. A loss-of-function mutation in myostatin reduces TNF{alpha} production and protects liver against obesity-induced insulin resistance. Diabetes 2009;58:1133–43. https://doi.org/10.2337/db08-0245 .
doi: 10.2337/db08-0245
McPherron, AC, Lee, SJ. Suppression of body fat accumulation in myostatin-deficient mice. J Clin Invest 2002;109:595–601. https://doi.org/10.1172/jci200213562 .
doi: 10.1172/jci200213562
Zhao, B, Wall, RJ, Yang, J. Transgenic expression of myostatin propeptide prevents diet-induced obesity and insulin resistance. Biochem Biophys Res Commun 2005;337:248–55. https://doi.org/10.1016/j.bbrc.2005.09.044 .
doi: 10.1016/j.bbrc.2005.09.044
Akpan, I, Goncalves, MD, Dhir, R, Yin, X, Pistilli, EE, Bogdanovich, S, et al.. The effects of a soluble activin type IIB receptor on obesity and insulin sensitivity. Int J Obes 2009;33:1265–73. https://doi.org/10.1038/ijo.2009.162 .
doi: 10.1038/ijo.2009.162
McPherron, AC. Metabolic functions of myostatin and GDF11. Immunol Endocr Metab Agents Med Chem. 2010;10:217–31. https://doi.org/10.2174/187152210793663810 .
doi: 10.2174/187152210793663810
Lee, SJ, McPherron, AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA 2001;98:9306–11. https://doi.org/10.1073/pnas.151270098 .
doi: 10.1073/pnas.151270098
Lee, SJ, Reed, LA, Davies, MV, Girgenrath, S, Goad, ME, Tomkinson, KN, et al.. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci USA 2005;102:18117–22. https://doi.org/10.1073/pnas.0505996102 .
doi: 10.1073/pnas.0505996102
Fournier, B, Murray, B, Gutzwiller, S, Marcaletti, S, Marcellin, D, Bergling, S, et al.. Blockade of the activin receptor IIb activates functional brown adipogenesis and thermogenesis by inducing mitochondrial oxidative metabolism. Mol Cell Biol 2012;32:2871–9. https://doi.org/10.1128/mcb.06575-11 .
doi: 10.1128/mcb.06575-11
McPherron, AC. Metabolic functions of myostatin and GDF11. Immunol Endocr Metab Agents Med Chem 2010;10:217–31. https://doi.org/10.2174/187152210793663810 .
doi: 10.2174/187152210793663810
Whittemore, LA, Song, K, Li, X, Aghajanian, J, Davies, M, Girgenrath, S, et al.. Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem Biophys Res Commun 2003;300:965–71. https://doi.org/10.1016/s0006-291x(02)02953-4 .
doi: 10.1016/s0006-291x(02)02953-4
Lee, SJ, McPherron, AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA 2001;98:9306–11. https://doi.org/10.1073/pnas.151270098 .
doi: 10.1073/pnas.151270098
Lee, SJ, Reed, LA, Davies, MV, Girgenrath, S, Goad, ME, Tomkinson, KN, et al.. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci USA 2005;102:18117–22. https://doi.org/10.1073/pnas.0505996102 .
doi: 10.1073/pnas.0505996102
Nunn, E, Jaiswal, N, Gavin, M, Uehara, K, Stefkovich, M, Drareni, K, et al.. Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism. Mol Metabol 2024;80:101880. https://doi.org/10.1016/j.molmet.2024.101880 .
doi: 10.1016/j.molmet.2024.101880
Petricoul, O, Nazarian, A, Schuehly, U, Schramm, U, David, OJ, Laurent, D, et al.. Pharmacokinetics and pharmacodynamics of bimagrumab (BYM338). Clin Pharmacokinet 2023;62:141–55. https://doi.org/10.1007/s40262-022-01189-0 .
doi: 10.1007/s40262-022-01189-0
Rooks, D, Petricoul, O, Praestgaard, J, Bartlett, M, Laurent, D, Roubenoff, R. Safety and pharmacokinetics of bimagrumab in healthy older and obese adults with body composition changes in the older cohort. J Cachexia Sarcopenia Muscle 2020;11:1525–34. https://doi.org/10.1002/jcsm.12639 .
doi: 10.1002/jcsm.12639
Rooks, DS, Laurent, D, Praestgaard, J, Rasmussen, S, Bartlett, M, Tankó, LB. Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy. J Cachexia Sarcopenia Muscle 2017;8:727–34. https://doi.org/10.1002/jcsm.12205 .
doi: 10.1002/jcsm.12205
Garito, T, Zakaria, M, Papanicolaou, DA, Li, Y, Pinot, P, Petricoul, O, et al.. Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes. Clin Endocrinol 2018;88:908–19. https://doi.org/10.1111/cen.13601 .
doi: 10.1111/cen.13601
Garito, T, Roubenoff, R, Hompesch, M, Morrow, L, Gomez, K, Rooks, D, et al.. Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals. Diabetes Obes Metabol 2018;20:94–102. https://doi.org/10.1111/dom.13042 .
doi: 10.1111/dom.13042
Heymsfield, SB, Coleman, LA, Miller, R, Rooks, DS, Laurent, D, Petricoul, O, et al.. Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Netw Open 2021;4:e2033457. https://doi.org/10.1001/jamanetworkopen.2020.33457 .
doi: 10.1001/jamanetworkopen.2020.33457
Wilding, JPH, Batterham, RL, Calanna, S, Davies, M, Van Gaal, LF, Lingvay, I, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384:989e1002. https://doi.org/10.1056/nejmoa2032183 .
doi: 10.1056/nejmoa2032183
Jastreboff, AM, Aronne, LJ, Ahmad, NN, Wharton, S, Connery, L, Alves, B, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387:205e16. https://doi.org/10.1056/nejmoa2206038 .
doi: 10.1056/nejmoa2206038
Jastreboff, AM, Kaplan, LM, Frías, JP, Wu, Q, Du, Y, Gurbuz, S, et al.. Triplehormone-receptor agonist retatrutide for obesity - a phase 2 trial. N Engl J Med 2023;389:514e26. https://doi.org/10.1056/nejmoa2301972 .
doi: 10.1056/nejmoa2301972
Wilding, JPH, Batterham, RL, Davies, M, Van Gaal, LF, Kandler, K, Konakli, K, et al.. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metabol 2022;24:1553e64. https://doi.org/10.1111/dom.14725 .
doi: 10.1111/dom.14725
Christoffersen, BØ, Sanchez-Delgado, G, John, LM, Ryan, DH, Raun, K, Ravussin, E. Beyond appetite regulation: targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss. Obesity (Silver Spring) 2022;30(4):841e57.
Sartori, R, Romanello, V, Sandri, M. Mechanisms of muscle atrophy and hypertrophy: implications in health and disease. Nat Commun 2021;12:330. https://doi.org/10.1038/s41467-020-20123-1 .
doi: 10.1038/s41467-020-20123-1
Safety and efficacy of bimagrumab and semaglutide in adults who are overweight or obese. NCT05616013 . U.S. National Library of Medicine; 2024. Available from: https://Clinicaltrials.Gov/Study/NCT05616013
Safety, pharmacokinetics and efficacy of bimagrumab in overweight and obese patients with type 2 diabetes. NCT03005288 . U.S. National Library of Medicine; 2024. Available from: https://clinicaltrials.gov/study/NCT03005288?intr=Bimagrumab&page=1&rank=6
Effect of bimagrumab on body composition, insulin sensitivity, and bone in adults with obesity. NCT05933499 . U.S. National Library of Medicine; 2024. Available from: https://clinicaltrials.gov/study/NCT05933499?intr=Bimagrumab&page=2&rank=14
An extension study of the efficacy, safety and tolerability of BYM338 (Bimagrumab) in patients with sporadic inclusion body myositis who previously participated in the core study CBYM338B2203. NCT02573467 . U.S. National Library of Medicine; 2024. Available from: https://clinicaltrials.gov/study/NCT02573467?intr=Bimagrumab&page=1&rank=2
Study of efficacy and safety of bimagrumab in patients after hip fracture surgery. NCT02152761 . U.S. National Library of Medicine; 2024. Available from: https://clinicaltrials.gov/study/NCT02152761?intr=Bimagrumab&page=1&rank=3
Effect of bimagrumab on body composition, insulin sensitivity, and bone in adults with obesity. NCT05933499 . U.S. National Library of Medicine; 2024 Available from: https://clinicaltrials.gov/study/NCT05933499?intr=Bimagrumab&page=2&rank=14
Clinical study of BYM338 for the treatment of unintentional weight loss in patients with cancer of the lung or the pancreas NCT01433263 . U.S. National Library of Medicine; 2024. Available from: https://clinicaltrials.gov/study/NCT01433263?intr=Bimagrumab&page=2&rank=13
BYM338 in chronic obstructive pulmonary disease (COPD) patients with cachexia NCT01669174 . U.S. National Library of Medicine; 2024. Available from: https://clinicaltrials.gov/study/NCT01669174?intr=Bimagrumab&page=2&rank=11